Publications

  1. Elsbernd P, Cacciaguerra L, Krecke KN, Chen JJ, Gritsch D, Lopez-Chiriboga AS, Sechi E, Redenbaugh V, Morris PP, Carter JL, Wingerchuk DM, Tillema JM, Valencia-Sanchez C, Thakolwiboon S, Pittock SJ, Flanagan EP. Cerebral enhancement in MOG antibody-associated disease. J Neurol Neurosurg Psychiatry. 2023 Dec 14; 95 (1):14-18
    View PubMed
  2. Houghton OM, Carter J, Dhamija R. Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations: Critical Role of Retina Specialists. J Vitreoretin Dis. 2023 Mar-Apr; 7 (2):171-177 Epub 2022 Dec 03
    View PubMed
  3. Elsbernd PM, Hoffman WR, Carter JL, Wingerchuk DM. Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review. Mult Scler Relat Disord. 2021 Feb; 48:102696 Epub 2020 Dec 16
    View PubMed
  4. Elsbernd PM, Carter JL. Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review. Biologics. 2021; 15:255-263 Epub 2021 June 30
    View PubMed
  5. Valencia-Sanchez C, Carter JL. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis. Expert Opin Pharmacother. 2020 Aug; 21 (12):1399-1405 Epub 2020 June 16
    View PubMed
  6. Valencia-Sanchez C, Goodman BP, Carter JL, Wingerchuk DM. The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations. Mult Scler. 2019 May; 25 (6):758-765 Epub 2019 Jan 18
    View PubMed
  7. Solomon AJ, Bourdette DN, Cross AH, Applebee A, Skidd PM, Howard DB, Spain RI, Cameron MH, Kim E, Mass MK, Yadav V, Whitham RH, Longbrake EE, Naismith RT, Wu GF, Parks BJ, Wingerchuk DM, Rabin BL, Toledano M, Tobin WO, Kantarci OH, Carter JL, Keegan BM, Weinshenker BG. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology. 2016 Sep 27; 87 (13):1393-9 Epub 2016 Aug 31
    View PubMed
  8. Cortez MM, Nagi Reddy SK, Goodman B, Carter JL, Wingerchuk DM. Autonomic symptom burden is associated with MS-related fatigue and quality of life. Mult Scler Relat Disord. 2015 May; 4: (3)258-63.
    View PubMed
  9. Popescu BF, Guo Y, Jentoft ME, Parisi JE, Lennon VA, Pittock SJ, Weinshenker BG, Wingerchuk DM, Giannini C, Metz I, Bruck W, Shuster EA, Carter J, Boyd CD, Clardy SL, Cohen BA, Lucchinetti CF. Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology. 2015 Jan 13; 84 (2):148-58 Epub 2014 Dec 10
    View PubMed
  10. Carter JL, Ali II, Isaacson RS, Safdieh JE, Finney GR, Sowell MK, Sam MC, Anderson HS, Shin RK, Kraakevik JA, Coleman M, Drogan O, Neurology Clerkship Director Survey Work Group of the Undergraduate Education Subcommittee of the American Academy of Neurology. Status of neurology medical school education: results of 2005 and 2012 clerkship director survey. Neurology. 2014 Nov 4; 83 (19):1761-6 Epub 2014 Oct 10
    View PubMed
  11. Reddy ST, Chao J, Carter JL, Drucker R, Katz NT, Nesbit R, Roman B, Wallenstein J, Beck GL. Alliance for clinical education perspective paper: recommendations for redesigning the "final year" of medical school. Teach Learn Med. 2014 Oct 2; 26(4):420-7.
    View PubMed
  12. Agnihotri SP, Dang X, Carter JL, Fife TD, Bord E, Batson S, Koralnik IJ. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Neurology. 2014 Aug 19; 83(8):727-32. Epub 2014 Jul 18.
    View PubMed
  13. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb; 89 (2):225-40
    View PubMed
  14. Thaera GM, Wingerchuk DM, Carter JL. Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis. Mult Scler Relat Disord. 2014 Jan; 3(1):107-9. Epub 2013 Jun 15.
    View PubMed
  15. Spritzer SD, Zarkou S, Ireland SP, Carter JL, Goodman BP. Autonomic dysfunction in adult-onset alexander disease: a case report and review of the literature. Clin Auton Res. 2013 Dec; 23 (6):333-8 Epub 2013 Aug 08
    View PubMed
  16. Bunyan RF, Popescu BF, Carter JL, Caselli RJ, Parisi JE, Lucchinetti CF. Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination. Arch Neurol. 2011 Apr; 68 (4):525-8
    View PubMed
  17. Zarkou S, Carter JL, Wellik KE, Demaerschalk BM, Wingerchuk DM. Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic. Neurologist. 2010 May; 16(3):212-4.
    View PubMed
  18. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose J, Choice Investigators. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomized, double-blind, placebo-controlled, add-on trial with interforon beta. www.thelancet.com/neurology. 2010 Feb 16.
  19. Thaera GM, Wellik KE, Carter JL, Demaerschalk BM, Wingerchuk DM. Do cannabinoids reduce multiple sclerosis-related spasticity? Neurologist. 2009 Nov; 15(6):369-71.
    View PubMed
  20. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009 Sep; 66 (9):1128-33
    View PubMed
  21. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D, Kastrukoff L, Duquette P, Freedman M, Debouverie M, Lubetski C, Edan G, Roullet E, Confavreux C, Thompson A, Blumhardt L, Hawkins S, Scott T, Wynn D, Cooper J, Thurston S, Elias S, Markowitz C, Mattson D, Noseworthy J, Shuster E, Carter J, Lublin F, Stuart W, Kaufman M, Birnbaum G, Rammohan K, Whitham R, Mihai C, Greenberg S, Smith C, Agius M, Van Den Noort S, Myers L, Nelson J, Goodin D, Arnason B, Bashir K, Lynch S, Coyle P, Kamin S, Sheremata W, Mitchell G, Goodman A, Kachuck N, Dunne P, Lindsey JW, Frohman E, Bowen J, Brooks B, Rose J, Moses H, Jeffrey D, Cross A, Lisak R, Vollmer T, Antel J, Cutter G, Metz L, McFarland H, Reingold S, Lublin FD, Vainrub I, Lambert L, Zhong F, Rasmituth J, Momin S, Kreitman R, Shifroni G, Pinchasi I, Stark Y. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007; 61(1):14-24.
  22. Castillo P, Woodruff B, Caselli R, Vernino S, Lucchinetti C, Swanson J, Noseworthy J, Aksamit A, Carter J, Sirven J, Hunder G, Fatourechi V, Mokri B, Drubach D, Pittock S, Lennon V, Boeve B. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006 Feb; 63 (2):197-202
    View PubMed
  23. Sandberg-Wollheim M, Bever C, Carter J, Farkkila M, Hurwitz B, Lapierre Y, Chang P, Francis G. Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis - The EVIDENCE study. J Neurol. 2005 Jan; 252(1):8-13.
    View PubMed
  24. Wingerchuk DM, Carter JL. Practical consultations: Multiple sclerosis. Semin Neurol. 2003 Sep; 23(3):253-64.
    View PubMed
  25. Sirven JI, Zimmerman RS, Carter JL, Drazkowski JF, Larson JS. MRI changes in status epilepticus. Neurology. 2003 Jun 10; 60 (11):1866
    View PubMed
  26. O’Connor P, Fleming P, Gray T, Jacobs L, Miller C, Munschauer F, Kinkel RP, Bolibrush D, Cohen J, Freedman M, Webb U, Rabinowicz H, Metz LM, Patry D, Yeung M, Peters S, Hashimoto S, Morrison W, Oger J, Panitch H, Costello K, Bever C, Stuart W, Court D, Stuart D, Simon J, Lucchinetti CF, Carter J, et al. MRI predictors of early conversion to clinically definite MS in the CHAMPS Placebo Group. Neurology. 2002 Oct 8; 59: (7)998-1005.
    View PubMed
  27. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001 Oct; 132 (4):463-71
    View PubMed
  28. Cohen JA, Carter JL, Kinkel RP, Schwid SR. Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. J Neuroimmunol. 1999 Jul 1; 98(1):29-36.
    View PubMed
  29. Noseworthy JH, O'Brien P, O'Brien P, Erickson BJ, Lee D, Sneve D, Ebers GC, Sneve D, Rice GP, Auty A, Hader WJ, Kirk A, Duquette P, Carter J, Francis G, Carter J, Metz L, Shuster E, Shuster E. The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology. 1998 Nov; 51 (5):1342-52
    View PubMed
  30. Stolp-Smith KA, Carter JL, Rohe DE, Knowland DP 3rd. Management of impairment, disability, and handicap due to multiple sclerosis. Mayo Clin Proc. 1997 Dec; 72 (12):1184-96
    View PubMed
  31. Hunter SF, Weinshenker BG, Carter JL, Noseworthy JH. Rational clinical immunotherapy for multiple sclerosis. Mayo Clin Proc. 1997 Aug; 72(8):765-80.
    View PubMed
  32. Crum BA, Carter JL. 26-year-old man with hyperpigmentation of skin and lower extremity spasticity. Mayo Clin Proc. 1997 May; 72(5):479-82.
    View PubMed
  33. Subbiah P, Wijdicks E, Muenter M, Carter J, Connolly S. Skin lesion with a fatal neurologic outcome (Degos' disease). Neurology. 1996 Mar; 46(3):636-40.
    View PubMed
  34. Cevette MJ, Robinette MS, Carter J, Knops JL. Otoacoustic emissions in sudden unilateral hearing loss associated with multiple sclerosis. J Am Acad Audiol. 1995 May; 6 (3):197-202
    View PubMed
  35. Carter JL. Disease modifying therapies for multiple sclerosis. CNS Drugs. 1995 Feb; 3:99-114.
  36. Carter JL, Noseworthy JH. Ventilatory dysfunction in multiple sclerosis. Clin Chest Med. 1994 Dec; 15(4):693-703.
    View PubMed
  37. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD, Baumel B, Hsu CY, Murphy F, Reader AT, Schapiro RT, Sibley WA, Stazio A, Trotter JL, Vollmer TL, Walshe TM. Tizanidine treatment of spasticity caused by multiple sclerosis--results of a double blind, placebo-controlled trial. Neurology. 1994 Nov; 44(Suppl 9):34-43.
    View PubMed
  38. Shefner JM, Carter JL, Krarup C. Peripheral abnormalities in patients with multiple sclerosis. Muscle Nerve. 1992; 15:73-76.
    View PubMed
  39. Carter JL, Rodriguez M. The immunopathology of multiple sclerosis. Curr Opin Neurol Neurosurg. 1991 Apr; 4:186-190.
  40. Carter JL, Rodriguez M. New drug therapies for multiple sclerosis. Drug Therapy. 1990; 20:31-43.
  41. Carter JL, Rodriguez M. Immunosuppressive treatment of multiple sclerosis. Mayo Clin Proc. 1989 Jun; 64 (6):664-9
    View PubMed
  42. Carter JL, Shefner JM, Krarup C. Cold-induced peripheral nerve damage: involvement of touch receptors of the foot. Muscle & Nerve. 1988 Oct; 11(10):1065-9.
    View PubMed
  43. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high-dose IV cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative six-year experience in 169 patients. Neurology. 1988; 38:7(Suppl 2):9-14.
  44. Carter JL, Dawson DM, Hafler DA, Fallis RJ, Stazzone L, Orav J, Weiner HL. Cumulative experience with high-dose IV cyclophosphamide and ACTH in chronic progressive multiple sclerosis. Ann N Y Acad Sci. 1988; 540:535-536.
    View PubMed
  45. Dawson DM, Carter JL, Hafler DA, Weiner HL. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. Riv Neurol. 1987 Mar-Apr; 57(2):88-91.
    View PubMed
  46. Brimijoin S, Carter J. Turnover of the molecular forms of acetylcholinesterase in the rat diaphragm. J Neurochem. 1982 Feb; 38(2):588-90.
    View PubMed
  47. Carter J, Lennon VA, Schreiber P, Brimijoin S. Content and release of acetylcholinesterase in skeletal muscle of rats with experimental autoimmune myasthenia gravis. Exp Neurol. 1982 Feb; 75(2):490-500.
    View PubMed
  48. Cater JL, Brimijoin S. Effects of acute and chronic denervation on release of acetylcholinesterase and its molecular forms in rat diaphragms. J Neurochem. 1981 Mar; 36(3):1018-25.
    View PubMed